OBJECTIVES: Ivabradine is a specific heart rate lowering agent that could reduce hospitalization and mortality rate due to heart failure (HF). The purpose of this study is systematically reviewing the published literature on the economic analysis of Ivabradine therapy for HF and summarizing the data of cost effectiveness analysis of this treatment. METHODS: A systematic literature review was conducted according to search strategy that included keywords related to “heart failure”, “Ivabradine” and “economic analysis” in the PubMed, Scopus and Web of Science databases. Two researchers separately selected the final articles according to the inclusion and exclusion criteria. The data related to economic model, cost, quality-adjusted life years (QALYs), lost years (LYs), horizon time of study and incremental cost-effectiveness ratio (ICER) was extracted. The currency was converted to US$ using purchasing power parities exchange rate. RESULTS: A total of 51 articles were found in primary search, of which 3 studies were met our criteria. The economic model, which applied in all of them was Markov model. The cost effectiveness of standard care with and without Ivabradine were evaluated. The clinical outcomes of these studies were hospitalization rate, adverse effect and mortality rate that have been considered in the Markov model.The medical costs have been calculated in the studies. Furthermore, the time horizon of studies were 10-year and over patient’s lifetime. The incremental QALYs, LYs and cost because of adding Ibavradine to standard care had a range of 0.18 to 0.28, 0.14 to 0.25 and -8594 to 4913 dollars. In addition, the maximum amount of ICER was 24920 dollars per QALY. All ICERs were lower than the threshold. CONCLUSIONS: Ivabradine added to standard treatment could be regarded as a cost effective option for heart failure therapy.